SC 13D/A | 2017-10-19 | Hodges Philip | Altimmune, Inc. | 583,691 | 3.7% | EDGAR |
SC 13G/A | 2017-08-23 | Novartis Bioventures Ltd | Altimmune, Inc. | 3,084,551 | 19.9% | EDGAR |
SC 13D/A | 2017-08-22 | Hodges Philip | Altimmune, Inc. | 1,319,711 | 8.5% | EDGAR |
SC 13D | 2017-05-15 | Hodges Philip | Altimmune, Inc. | 1,319,711 | 8.5% | EDGAR |
SC 13G | 2017-05-15 | Truffle Capital S.A.S. | Altimmune, Inc. | 1,560,946 | 10.1% | EDGAR |
SC 13G | 2017-05-15 | OFCO Club V | Altimmune, Inc. | 1,164,190 | 7.5% | EDGAR |
SC 13G | 2017-05-08 | Novartis Bioventures Ltd | Altimmune, Inc. | 1,867,854 | 11.1% | EDGAR |
SC 13G/A | 2017-02-14 | Nantahala Capital Management, LLC | PHARMATHENE, INC | 3,202,045 | 4.8% | EDGAR |
SC 13G | 2017-02-14 | RENAISSANCE TECHNOLOGIES LLC | PHARMATHENE, INC | 3,347,141 | 5.0% | EDGAR |
SC 13G/A | 2017-02-10 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 3,262,422 | 4.9% | EDGAR |
SC 13G | 2016-10-19 | JFL Capital Management, LLC | PHARMATHENE, INC | 3,315,203 | 5.0% | EDGAR |
SC 13D/A | 2016-03-30 | MPM BIOVENTURES III L.P. | PHARMATHENE, INC | 0 | 0.0% | EDGAR |
SC 13G/A | 2016-02-16 | Nantahala Capital Management, LLC | PHARMATHENE, INC | 3,389,364 | 5.3% | EDGAR |
SC 13D/A | 2016-02-12 | MPM BIOVENTURES III L.P. | PHARMATHENE, INC | 197,849 | 0.3% | EDGAR |
SC 13G/A | 2015-02-17 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 7,981,035 | 12.6% | EDGAR |
SC 13G/A | 2014-08-18 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 7,966,035 | 14.1% | EDGAR |
SC 13G | 2014-04-02 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 5,244,835 | 9.8% | EDGAR |
SC 13D/A | 2013-12-02 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 5,244,835 | 10.0% | EDGAR |
SC 13D/A | 2013-11-27 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 5,244,835 | 10.0% | EDGAR |
SC 13D/A | 2013-11-25 | PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | PHARMATHENE, INC | 5,244,835 | 10.0% | EDGAR |